SkinCoat
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
SkinCoat - overview
Location
-, -, Ireland
Primary Industry
Healthcare Specialists
About
Founded by Julie O'Sullivan and based in Ireland, SkinCoat provides a probiotic cream for managing eczema symptoms to soothe redness, itching, and inflammation. In November 2024, SkinCoat raised EUR 1 million in venture funding from Enterprise Ireland. The company’s primary product includes a topical probiotic cream that is designed to alleviate eczema symptoms by promoting a microbiome-friendly approach. The firm’s product is developed in collaboration with UCC’s Department of Microbiology and APC Microbiome.
SkinCoat’s product addresses limitations of conventional treatments like steroids and antibiotics, aiming to reduce reliance on solutions contributing to antimicrobial resistance. The organization plans to use the November 2024 funding to collaborate with organizations and launch the product on the market.
Current Investors
Enterprise Ireland
Primary Industry
Healthcare Specialists
Sub Industries
Beauty & Hygiene, Dermatology
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.